pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,369 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1566Endpoints1225BioSpace565Fierce Biotech562BioPharma Dive467raps192onclive165fda recalls
therapy area
allOncology10451Rare Disease2757Immunology2463Cardiology2287Hematology1887Pulmonology1875Vaccines
  • Merck pulls Recarbrio antibiotic from U.S. market, raising concerns over superbug resistance
    Merck announced it has stopped supplying Recarbrio in the United States earlier this month. Recarbrio, a three‑drug combination injection approved seven years ago, is used for severe infections su…
    STAT · 23d agoNegative↗ source
  • AbbVie receives FDA approval for Parkinson’s drug Juvmo, a Cerevel acquisition asset
    AbbVie has secured FDA approval for tavapadon, marketed as Juvmo, for the treatment of Parkinson’s disease in adults. The decision follows positive results from the Phase 3 TEMPO trial. In the piv…
    BioSpace · 23d agoApprovalPositive↗ source
← prev
page 15 of 95
next →
103
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology871
Endocrinology & Metabolism691
Pain656
Nephrology645
  • Kodiak Sciences' zenkuda and tabirafusp-ted match Eylea in Phase 3, sending stock up 166%
    Kodiak Sciences announced Phase 3 results for two investigational eye‑disease drugs, zenkuda (anti‑VEGF antibody biopolymer conjugate) and tabirafusp‑ted (anti‑IL‑6/VEGF bispecific), which performe…
    BioSpace · 23d agoPositive readoutPositive↗ source
  • Mirum receives FDA approval for Atebrioz, third therapy for ultra-rare bone disease FOP
    Mirum Pharmaceuticals announced that the U.S. Food and Drug Administration approved its ALK2 inhibitor, zilurgisertib, to be marketed as Atebrioz, for the treatment of fibrodysplasia ossificans pro…
    BioSpace · 23d agoApprovalPositive↗ source
  • Merck signs up to $2.13 billion deal with SciBrunch for preclinical KRAS inhibitor SPR2015
    Merck announced it has completed a deal with Chinese biotech SciBrunch Therapeutics, paying $400 million upfront for exclusive global rights to develop, manufacture and commercialize SciBrunch’s pr…
    BioSpace · 23d agoDealPositive↗ source
  • Novo Nordisk rebrands GLP-1 therapy Wegovy as weight-loss product, positioning it as lifestyle drug
    GLP-1 drugs have transformed the lives of millions and were originally promoted as medicines for obesity, a medical condition. Recent advertising campaigns are now presenting these drugs as genera…
    STAT · 23d agoNeutral↗ source
  • Rising health insurance premiums and a private equity hospital chain's shift to nonprofit highlight bleak outlook for US healthcare costs
    Bob Herman's latest Health Care Inc. newsletter warns that employer-sponsored health insurance is becoming increasingly unaffordable, with premiums climbing sharply. The piece cites a series called…
    STAT · 23d agoNegative↗ source
  • Merck and Daiichi Sankyo pull accelerated approval request for lung cancer ADC
    Merck and Daiichi Sankyo have voluntarily withdrawn their application for accelerated approval of the antibody-drug conjugate ifinatamab deruxtecan. The FDA indicated that the data package did not…
    BioSpace · 23d agoRegulatoryNegative↗ source
  • Ultragenyx gains FDA approval for Fayuvi, a Sanfilippo syndrome A therapy, easing impact of recent Angelman setback
    Ultragenyx announced that the FDA has approved its drug Fayuvi for treating Sanfilippo syndrome type A, a rare neurodegenerative condition affecting children. The approval marks the company's first…
    BioSpace · 23d agoApprovalPositive↗ source
  • AbbVie’s once-daily Parkinson’s pill receives FDA approval
    AbbVie announced that the U.S. Food and Drug Administration has granted approval for its once‑daily oral therapy for Parkinson’s disease. The decision allows the product to be marketed in the Unite…
    STAT · 23d agoApprovalPositive↗ source
  • GLP-1 drugs shift from obesity treatment to lifestyle products, prompting setbacks for Merck and Daiichi
    The column notes that GLP-1 medicines, originally marketed to treat obesity as a medical condition, are now being promoted more as general lifestyle enhancers for appearance and wellbeing. Novo No…
    STAT · 23d agoNegative↗ source
  • AI tools that aid vaccine design could also accelerate creation of bioweapons, warns former White House Covid adviser
    Ashish K. Jha, a former White House Covid‑19 response coordinator and senior fellow at Harvard Kennedy School, cautions that artificial intelligence is lowering the barriers that kept biological we…
    STAT · 23d agoNegative↗ source
  • Biopharma chases new immunology targets as Humira and Dupixent set high bar
    Johnson & Johnson, Pfizer, Argenx and several other companies are expanding their immunology pipelines, seeking new targets and improvements to capture part of the market driven by AbbVie’s Humira…
    BioSpace · 23d agoPositive↗ source
  • Trump administration pulls nearly $1 billion from HHS programs for immigrants and diversity
    The White House announced a reversal of almost $1 billion in spending that Congress had previously approved for the Department of Health and Human Services. The reduction was made late on Friday ni…
    STAT · 23d agoRegulatoryNegative↗ source
  • Study finds toxic metal exposure persists months after Maui wildfires
    University of Hawai‘i researchers examined urine samples from about 1,400 adults as part of the Maui Wildfire Exposure Study, one of the nation’s largest investigations of post‑fire health effects.…
    STAT · 23d agoNegative↗ source
  • Regenerative medicine requires diagnostics and product characterization beyond stem cell basics
    Stem cell therapies are often portrayed as a single treatment, but they actually vary widely in tissue source, cell passage, viability and delivery methods. Experts say a credible regenerative app…
    BioSpace · 23d agoNeutral↗ source
  • BioSpace report examines factors driving employee engagement in life sciences firms
    BioSpace released a new report titled "What Powers Employee Engagement" that looks at what influences staff morale in the life‑science sector. The study draws on data from the 2027 Best Places to…
    BioSpace · 23d agoNeutral↗ source
  • Trump administration seeks Supreme Court stay on gender-affirming care restrictions in federal prisons
    The Trump administration filed an emergency petition with the Supreme Court asking it to pause a district judge’s order that requires continued provision of gender-affirming medical treatments to i…
    STAT · 23d agoRegulatoryNeutral↗ source
  • Researchers identify previously unseen structure in the human heart
    An author of an opinion piece reports that a close visual inspection of the heart revealed a previously unrecognized anatomical structure. The discovery was made without new imaging technology, sim…
    STAT · 23d agoPositive↗ source
  • Former CDC investigator warns that gaps in public-health readiness leave the U.S. vulnerable to future biothreats
    Daniel Jernigan, a former CDC scientist who helped investigate the 2001 anthrax mailings, reflects on the lessons learned two and a half decades later. The anthrax letters, sent from New Jersey to…
    STAT · 25d agoNeutral↗ source
  • Trump administration cancels nearly $1 billion of congressional spending, targeting refugee and immigrant services
    The White House announced on Friday that it is using a rarely invoked authority to rescind almost $1 billion in funding that Congress had approved earlier. The cuts focus mainly on Health and Huma…
    STAT · 25d agoNegative↗ source
  • FDA approves Lilly's once-weekly basal insulin Onswik for adults with type 2 diabetes
    The U.S. Food and Drug Administration has granted approval to Eli Lilly’s Onswik, a basal insulin designed for once-weekly injection in adults with type 2 diabetes. The new formulation offers patie…
    STAT · 26d agoApprovalPositive↗ source
  • Genentech signs $55M upfront deal with AI firm Earendil Labs to develop bispecific cancer antibodies, potential total value over $1.5B
    Genentech announced a partnership with AI‑driven Earendil Labs that includes a $55 million upfront payment and could exceed $1.5 billion when development, regulatory and sales milestones are met. T…
    BioSpace · 26d agoDealPositive↗ source
  • UN-backed agency secures sub-licensing deals for generic Roche flu drug across 129 low- and middle-income countries
    An agency supported by the United Nations has finalized sub-licensing contracts with eleven drug manufacturers to create generic versions of Roche’s influenza medication Xofluza. The agreements al…
    STAT · 26d agoDealPositive↗ source
  • Carvykti shows 5-year survival in half of multiple myeloma patients in Phase 2 study
    Johnson & Johnson and Legend Biotech reported that 10 of the 20 multiple myeloma patients treated with a single dose of Carvykti remained alive after a median follow‑up of 60.7 months, representing…
    BioSpace · 26d agoPositive readoutPositive↗ source